NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis | MENAFN.COM
NMD Pharma raises $47M in series A investment round from INKEF and existing investors, to advance treatments of neuromuscular disorders | Nordic 9
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma picked as Biotech of the Week by Labiotech.eu — NMD Pharma
NMD Pharma - Inkef capital
Prominent Canadian researcher in Denmark: Why I left a top job in California
NMD Pharma A/S | LinkedIn
Well-financed biotech company to enter the clinic in 2020
Detailed Description | NMD-GPS
NMD Pharma Information | NMD Pharma Profile
Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email
NMD Pharma company information, funding & investors | Dealroom.co
Klaus Wilhardt - Corporate identity, Design, Logo/navnetræk og designguides
NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
NMD Pharma - PIR International
Neuromuscular Drug Development Summit (NMD) - Pharma Journalist
NMD Pharma - Inkef capital
NMD Pharma
Company Presentation
Labiotech.eu on Twitter: "NMD Pharma, from @AarhusUni, is willing to tackle Neuromuscular Transmission Disorders #BioEquity2016… "
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma - Capnova
Big deal: NMD flexes series A muscles - Global University Venturing
Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"
NMD Pharma | The Org
